Cholestin public comments to be accepted by FDA until Jan. 30.
This article was originally published in The Tan Sheet
Executive Summary
CHOLESTIN PUBLIC COMMENTS TO BE ACCEPTED BY FDA UNTIL JAN. 30, according to an agency notice in the Jan. 13 Federal Register. The notice invites comments on the regulatory status of the product, marketed by Pharmanex as a dietary supplement for cholesterol reduction, and provides additional time for submissions. The agency disclosed it was initiating an administrative proceeding on the issue in a Nov. 14 letter to Pharmanex and said it would target the end of 1997 for a final decision ("The Tan Sheet" Dec. 1, 1997, p. 6). The letter responded to a citizen petition from Pharmanex requesting a stay of enforcement action against Cholestin.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning